--Chardan Adjusts PT on Solid Biosciences to $15 From $6, Updates Thesis Ahead of Data Release for Gene Therapy Candidate SGT-003; Maintains Buy Rating
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations,
you may see comments from our Community Managers.